Douglas Kerr Sells 3,745 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 3,745 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $24.35, for a total transaction of $91,190.75. Following the completion of the sale, the insider directly owned 163,854 shares in the company, valued at $3,989,844.90. This trade represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Douglas Kerr also recently made the following trade(s):

• On Tuesday, September 8th, Douglas Kerr sold 1,290 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.88, for a total transaction of $24,355.20.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $19.19 on Thursday. Dyne Therapeutics, Inc. has a fifty-two week low of $11.92 and a fifty-two week high of $27.31. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The company has a 50 day moving average price of $24.77 and a 200 day moving average price of $20.52. The stock has a market capitalization of $3.58 billion, a P/E ratio of -5.76 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.47 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DYN shares. Raymond James Financial reissued a “strong-buy” rating and set a $37.00 target price on shares of Dyne Therapeutics in a research note on Tuesday. Morgan Stanley dropped their target price on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a research report on Wednesday. Robert W. Baird cut their price target on shares of Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Finally, Royal Bank Of Canada lowered their price objective on shares of Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $32.17.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Hilton Head Capital Partners LLC purchased a new stake in shares of Dyne Therapeutics during the first quarter worth approximately $26,000. Strs Ohio acquired a new position in Dyne Therapeutics during the 4th quarter worth approximately $51,000. Allworth Financial LP purchased a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at approximately $62,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Dyne Therapeutics in the 4th quarter valued at $84,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Key Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada maintained an “outperform” rating, although it reduced its price target from $35 to $30. RBC said Dyne’s DYNE-101, or z-basivarsen, has important differences from Novartis’ program that could support better outcomes. RBC analysis of Dyne’s DM1 approach
• Positive Sentiment: Dyne is scheduled to present six- and 12-month ACHIEVE trial data for z-basivarsen at the World Muscle Society and AANEM meetings beginning September 29-30. The company expects topline results from its fully enrolled registrational expansion cohort in the first quarter of 2027. Dyne ACHIEVE data announcement
• Neutral Sentiment: JPMorgan downgraded DYN from “neutral” to “underweight” and cut its price target from $17 to $10, while RBC remained bullish. The sharply conflicting views highlight significant uncertainty ahead of Dyne’s clinical updates. JPMorgan downgrade report
• Neutral Sentiment: Call-option activity increased dramatically, with traders purchasing more than 20,000 calls versus an average of roughly 464. This may indicate speculative expectations for a rebound or favorable clinical data, but it does not establish a fundamental improvement.
• Negative Sentiment: Investors appear to be treating the Novartis Phase 3 failure as a warning for the DM1 drug class, causing a sharp decline in Dyne shares despite the company’s upcoming data. Report on rival DM1 trial failure
• Negative Sentiment: Several insiders, including CEO John Cox, reported stock sales. The filings state that the sales were made to cover tax withholding on vested equity awards, reducing their negative significance, but the cluster may add to cautious sentiment.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.